Galapagos NV
Belgium · BE0003818359 · reports in EUR · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue rose from €276M to €1.1B in the year to Dec 31, 2025, from a small base.
- Return on equity
- It earned 9.9% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 95% of its assets, and operations used cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2024 | Dec 2025 | |
|---|---|---|
| Revenue | €276M | €1.1B |
| Operating profit | −€188M | €295M |
| Net profit to shareholders | €74M | €321M |
| Earnings per share | €1.12 | €4.87 |
| Cash from operations | −€320M | −€257M |
| Capital spending | €17M | €14M |
| Cash | €64M | €88M |
| Total assets | €4.1B | €3.4B |
| Equity | €2.9B | €3.2B |
What they do
In the company's own words, from the annual report.
Wij zijn een biotechnologiebedrijf dat zich toelegt op het leveren van geneesmiddelen aan patiënten met ernstige aandoeningen in therapeutische gebieden waar de medische behoeste hoog is.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.